Erectile dysfunction medication
Spedra is a new medication that is targeted at treating erectile dysfunction. The active ingredient of the medication is Avanafil.
The patent is held by the pharmaceutical company Vivus. The company’s focus is to bring next-generation pharmaceuticals and treatments.
Spedra works similarly to other PDE-5 inhibitors, which block the work of enzymes that, by metabolising a certain chemical, might not make the muscle of the penis relax completely. By blocking this process and letting the chemical guanosine monosphate (cGMP) to build up, the consequences are: more penis relaxation, which leads to more blood filling the blood vessel in the penis which, in turn, leads to a more satisfactory erection.
Spedra side effects are quite rare but the most common are
Even more rarely, people have reported backaches. It is of the outmost importance that you consult with your doctor about this medical treatment. It is a prescription medication and there are several medications and other medical conditions that must be taken into consideration before considering Spedra as an erectile dysfunction treatment. For example, if you take any other medications which contain nitrates or you are a man affected by heart disease then Spedra might not be for you.
Spedra is the first medication said to be a next-generation treatment compared to other PDE-5 inhibitors. This is because patients in the clinical trial did not report other side effects that are commonly experienced when taking PDE-5 inhibitors (such as blurred vision or loss of hearing). Therefore it seems to have less side effects than other PDE-5 inhibitors. Another characteristic of this treatment that might be helpful to know is the fact that Spedra acts quite quickly, so it is indicated to be taken 30 minutes before sexual arousal. However, some patients experienced its effect already after 15 minutes.
The latest news on Spedra is that its marketing authorisation has been approved in Europe at the end of last month (June 2013).
For more information on Spedra given by the European Medicines Agency you can read this document.
Vivus has already signed a deal with a company named Menarini, which will hopefully bring the medication onto the UK market by early next year.